GlobalData on MSN
Recursion CEO details novel Phase III endpoint for rare disease drug
The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic ...
If you picked Recursion Pharmaceuticals for its AI-first pitch and deep pharma ties, the past year has probably felt rough.
Q3 earnings and clinical updates put Recursion Pharmaceuticals (RXRX) in focus Recursion Pharmaceuticals (RXRX) just delivered a busy Q3 2026, pairing an earnings update and ongoing losses with fresh ...
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
StockStory.org on MSN
Why is Recursion Pharmaceuticals stock rocketing higher today?
What happened? Shares of Recursion Pharmaceuticals jumped 7.2% in the afternoon session after the company aligned with the FDA on the design of its registrational Phase 3 trial of REC-4881, an ...
Recursion Pharmaceuticals, Inc () has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals Earnings Call Highlights Clinical Momentum ...
Recursion Pharmaceuticals has aligned with the US Food and Drug Administration on the design of its phase 3 trial of REC-4881 ...
AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...
Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results